Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.64 |
| ▸ | MEN1 | O00255 | 8/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 9/20 | 0.62 |
| ▸ | HTT | P42858 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.62 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447278 | 1.00 | PIK3CG (0.72) | PIK3CGKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL1638640 | 1.00 | PIK3CG (0.72) | PIK3CGKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL13959744 | 0.89 | PIK3CG (0.64) | PIK3CGKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL685298 | 0.88 | KMT2A (0.61) | PIK3CGKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL26974435 | 0.88 | PIK3CG (0.69) | PIK3CGKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL684886 | 0.88 | MAPT (0.72) | PIK3CGKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL684793 | 0.88 | PIK3CG (0.63) | PIK3CGKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL684554 | 0.88 | KMT2A (0.65) | PIK3CGKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL1638608 | 0.88 | KMT2A (0.65) | PIK3CGKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL1638610 | 0.88 | KMT2A (0.65) | PIK3CGKMT2AMEN1KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962677-B2 | Methods of restoring cognitive ability using non-peptidic compounds | ACUMEN PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | claimed |
| EP-2173340-B1 | METHODS OF ENHANCING COGNITIVE FUNCTION USING NON-PEPTIDIC COMPOUNDS | ACUMEN PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | claimed |
| US-20150320860-A1 | METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 | MERCK SHARP AND DOHME CORP. | 2015-11-12 | — | — | US | disclosed |
| EP-2928561-A1 | METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 | Acumen Pharmaceuticals, Inc. (US) | 2015-10-14 | — | — | EP | disclosed |
| US-8962677-B2 | Methods of restoring cognitive ability using non-peptidic compounds | ACUMEN PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2014089149-A1 | METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 | ACUMEN PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| EP-2173340-B1 | METHODS OF ENHANCING COGNITIVE FUNCTION USING NON-PEPTIDIC COMPOUNDS | ACUMEN PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2194975-A2 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS | Acumen Pharmaceuticals, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009009768-A2 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090018084-A1 | METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS | ACUMEN PHARMACEUTICALS, INC. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018084-A1 | METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS | BCHE, APP, ACHE | PIK3CG 4707/4885KMT2A 2509/4885MEN1 2353/4885 |
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | APP, APBA1, BACE1 | PIK3CG 4847/4885KMT2A 3625/4885MEN1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.